Skip to main content
    M

    Medtronic PLC (MDT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $102.90
    +0.04 (+0.04%)

    Market Cap: $131.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Medtronic PLC (MDT) Earnings: Report Dates and Results

    Updated Sep 1, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Medtronic (MDT) is confirmed to report earnings on Nov 24, 2026, before the open. In the quarter ended Jul 31, 2026, Medtronic reported EPS of $1.45, above the $1.39 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(35/39)
    Avg Surprise
    +9.32%
    Streak
    17 Q

    Upcoming Estimates

    Reports Nov 24, 2026 before openPeriod ending Oct 31, 2026
    EPS Consensus$1.33
    Range$1.32 - $1.34
    25 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.35-1.1%
    60d ago$1.33+0.1%
    30d ago$1.33-0.0%
    7d ago$1.330.0%
    Current$1.33
    Revenue Consensus
    $9.48B
    Range$9.42B - $9.54B
    24 analysts
    Reports Feb 15, 2027 (est.)Period ending Jan 31, 2027
    EPS Consensus$1.42
    Range$1.40 - $1.48
    24 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$1.43-0.5%
    60d ago$1.42-0.0%
    30d ago$1.42-0.0%
    7d ago$1.420.0%
    Current$1.42
    Revenue Consensus
    $9.52B
    Range$9.46B - $9.70B
    23 analysts

    Next Report

    MDT has a confirmed report date of Nov 24, 2026, before the open. Analysts' consensus for the quarter ended Oct 31, 2026 is 2.2% below the $1.36 reported for the quarter ended Oct 31, 2025.

    MDT Earnings Call

    The latest MDT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MDT beat 36, missed 2 and matched 2. Revenue for the quarter ended Jul 31, 2026 was $9.76B, up 13.8% from $8.58B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jul 31, 2026$1.45$1.39$1.37 - $1.40+4.32%Beat+15.1%241 up, 1 downSep 1, 2026$9.76B
    Apr 30, 2026$1.55$1.54$1.52 - $1.66+0.65%Beat-4.3%210 up, 2 downJun 3, 2026$9.81B
    Jan 31, 2026$1.36$1.34$1.33 - $1.36+1.49%Beat-2.2%260 up, 4 downFeb 17, 2026$9.02B
    Oct 31, 2025$1.36$1.31$1.31 - $1.32+3.82%Beat+7.9%260 up, 1 downNov 18, 2025$8.96B
    Jul 31, 2025$1.26$1.23$1.22 - $1.24+2.44%Beat+2.4%242 up, 0 downAug 19, 2025$8.58B
    Apr 30, 2025$1.62$1.58$1.56 - $1.59+2.53%Beat+11.0%271 up, 0 downMay 21, 2025$8.93B
    Jan 31, 2025$1.39$1.36$1.35 - $1.37+2.21%Beat+6.9%261 up, 1 downFeb 18, 2025$8.29B
    Oct 31, 2024$1.26$1.25$1.23 - $1.27+0.80%Beat+0.8%281 up, 1 downNov 19, 2024$8.40B
    Jul 31, 2024$1.23$1.20$1.18 - $1.21+2.50%Beat+2.5%281 up, 0 downAug 20, 2024$7.92B
    Apr 30, 2024$1.46$1.45$1.44 - $1.46+0.69%Beat-7.0%270 up, 0 downMay 23, 2024$8.59B
    Jan 31, 2024$1.30$1.26$1.25 - $1.27+3.17%Beat0.0%270 up, 0 downFeb 20, 2024$8.09B
    Oct 31, 2023$1.25$1.18$1.16 - $1.20+5.93%Beat-3.8%271 up, 0 downNov 21, 2023$7.98B
    Jul 31, 2023$1.20$1.11$1.10 - $1.13+8.11%Beat+6.2%271 up, 0 downAug 22, 2023$7.70B
    Apr 30, 2023$1.57$1.55$1.54 - $1.57+1.29%Beat+3.3%251 up, 0 downMay 25, 2023$8.54B
    Jan 31, 2023$1.30$1.27$1.25 - $1.32+2.36%Beat-5.1%231 up, 1 downFeb 21, 2023$7.73B
    Oct 31, 2022$1.30$1.28$1.25 - $1.29+1.56%Beat-1.5%250 up, 1 downNov 22, 2022$7.58B
    Jul 31, 2022$1.13$1.12$1.10 - $1.16+0.89%Beat-19.9%230 up, 1 downAug 23, 2022$7.37B
    Apr 30, 2022$1.52$1.56$1.54 - $1.57-2.56%Miss+1.3%230 up, 1 downMay 26, 2022$8.09B
    Jan 31, 2022$1.37$1.37$1.34 - $1.380.00%In line+6.2%130 up, 4 downFeb 22, 2022$7.76B
    Oct 31, 2021$1.32$1.29$1.27 - $1.30+2.33%Beat+29.4%22N/ANov 23, 2021$7.85B
    Jul 31, 2021$1.41$1.32$1.31 - $1.37+6.82%Beat+127.4%25N/AAug 24, 2021$7.99B
    Apr 30, 2021$1.50$1.42$1.39 - $1.48+5.63%Beat+158.6%26N/AMay 27, 2021$8.19B
    Jan 31, 2021$1.29$1.15$1.11 - $1.24+12.17%Beat-10.4%23N/AFeb 23, 2021$7.78B
    Oct 31, 2020$1.02$0.80$0.71 - $1.02+27.50%Beat-22.1%22N/ANov 24, 2020$7.65B
    Jul 31, 2020$0.62$0.18-$0.02 - $0.42+244.44%Beat-50.8%20N/AAug 25, 2020$6.51B
    Apr 30, 2020$0.58$0.75$0.12 - $1.63-22.67%Miss-62.3%23N/AMay 21, 2020$6.00B
    Jan 31, 2020$1.44$1.38$1.38 - $1.39+4.35%Beat+11.6%23N/AFeb 18, 2020$7.72B
    Oct 31, 2019$1.31$1.28$1.27 - $1.30+2.34%Beat+7.4%21N/ANov 19, 2019$7.71B
    Jul 31, 2019$1.26$1.19$1.18 - $1.20+5.88%Beat+7.7%21N/AAug 20, 2019$7.49B
    Apr 30, 2019$1.54$1.47$1.43 - $1.48+4.76%Beat+8.5%25N/AMay 23, 2019$8.15B
    Jan 31, 2019$1.29$1.24$1.22 - $1.25+4.03%Beat+10.3%25N/AFeb 19, 2019$7.55B
    Oct 31, 2018$1.22$1.15$1.14 - $1.16+6.09%Beat+14.0%23N/ANov 20, 2018$7.48B
    Jul 31, 2018$1.17$1.11$1.10 - $1.13+5.41%Beat+4.5%22N/AAug 21, 2018$7.38B
    Apr 30, 2018$1.42$1.39$1.37 - $1.40+2.16%Beat+6.8%21N/AMay 24, 2018$8.14B
    Jan 31, 2018$1.17$1.17$1.15 - $1.180.00%In line+4.5%21N/AFeb 20, 2018$7.37B
    Oct 31, 2017$1.07$1.03$0.87 - $1.09+3.88%Beat-4.5%21N/ANov 21, 2017$7.05B
    Jul 31, 2017$1.12$1.08$1.07 - $1.12+3.70%Beat+8.7%22N/AAug 22, 2017$7.39B
    Apr 30, 2017$1.33$1.31$1.29 - $1.34+1.53%Beat+4.7%20N/AMay 25, 2017$7.92B
    Jan 31, 2017$1.12$1.11N/A+0.90%Beat+5.7%N/AN/AFeb 21, 2017$7.28B
    Oct 31, 2016$1.12$1.11N/A+0.90%Beat+8.7%N/AN/ANov 22, 2016$7.34B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Apr 30, 2026 was $5.53, within 4 cents of the year before. It was $4.60 for the year ended Apr 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Apr 30, 2026$5.53N/A
    Apr 30, 2025$5.50+5.6%
    Apr 30, 2024$5.21-1.7%
    Apr 30, 2023$5.30-5.7%
    Apr 30, 2022$5.62+26.9%
    Apr 30, 2021$4.43-3.5%
    Apr 30, 2020$4.59-12.1%
    Apr 30, 2019$5.22+9.2%
    Apr 30, 2018$4.78+3.9%
    Apr 30, 2017$4.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,35814
    2026Q2Jun 30, 20269,56311
    2026Q1Mar 31, 20268,51214
    2025Q4Dec 31, 20259,44116
    2025Q3Sep 30, 20258,25316
    2025Q2Jun 30, 20257,66519
    2025Q1Mar 31, 20257,37419
    2024Q4Dec 31, 20248,52115

    2026Q3 Earnings Call

    Opening remarks

    Geoffrey Martha Chief Executive Officer Beyond cash, we're also making material progress with Symplicity for hypertension and Altaviva for urge urinary incontinence. Symplicity delivers a one-time durable minimally invasive treatment for hypertension and represents one of our largest growth drivers. This is going to be a contributor for years to come given the 18 million U.S. patients with uncontrolled hypertension. We're seeing strong patient outcomes in the field and the value proposition resonates with both physicians and patients. We have strong and growing clinical data, a broad label and expanding reimbursement all in hand. We've built the foundation. Now we're focused on growing this new segment and transforming the hypertension treatment paradigm. We've recently activated our direct-to-consumer Go Beyond campaign in key markets around the U.S., which is resulting in a 50x increase in website visits versus the prior quarter. So a lot of interest coming in from patients. Building a new market takes time, but that is something Medtronic knows how to do exceptionally well. In parallel to building out this new market, we're innovating for the long term. First, with our transradial catheter, which is on track to launch in the second half of fiscal year '27, and with our Spiral Gemini trial evaluating multi-organ ablation to further boost efficacy. Similarly, we are scaling Altaviva, our tibial neurostimulation device. Altaviva is a simple yet transformational option for treating urge urinary incontinence, a condition that affects about 1 million people in the U.S. Altaviva is a very small device that requires no imaging, no sedation, activates the same day, is MRI ready and offers up to 15 years of battery life, the longest in its category. We are receiving great early interest and feedback from both physicians and patients. We are training doctors, educating and supporting hospital staff and investing in omnichannel consumer activation. It's early days for both of these launches, and we are focused on disciplined execution to convert early traction into procedures. Pivoting to Hugo. This quarter, our Hugo robot received FDA clearance for urologic surgical procedures, enabling us to begin our purposeful U.S. launch. Today, I'm excited to share that we've already completed our first installations and initial cases. As noted in our release this morning, last week we completed our first cases at Cleveland Clinic, where surgeons echoed the strong feedback we continuously receive on Hugo's differentiation across multiple areas. This includes its flexibility, portability, open console and, of course, our trusted instrumentation. Hugo is especially compelling when paired with our Touch Surgery Digital Ecosystem, an AI-powered data connectivity and analytics technology that is unique to Medtronic. This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.

    Frequently Asked Questions About MDT

    When is Medtronic's next earnings date?

    Medtronic's next earnings report is confirmed for Nov 24, 2026, before the open.

    Did MDT beat earnings estimates last quarter?

    Yes. Medtronic reported EPS of $1.45 for the quarter ended Jul 31, 2026, above the $1.39 estimate, a 4.32% surprise.

    What EPS do analysts expect from MDT next quarter?

    The consensus EPS estimate for Medtronic for the quarter ended Oct 31, 2026 is $1.33 from 25 analysts, with estimates from $1.32 to $1.34.

    How often does MDT beat earnings estimates?

    Medtronic beat the EPS estimate in each of the last 17 quarters, with an average surprise of +2.63%.

    Does MDT report before or after the market opens?

    Medtronic is confirmed to report on Nov 24, 2026, before the market opens.